Robecosam Ag buys $18,692,120 stake in PerkinElmer (PKI)

PerkinElmer (PKI) : Robecosam Ag scooped up 8,522 additional shares in PerkinElmer during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 12, 2016. The investment management firm now holds a total of 343,542 shares of PerkinElmer which is valued at $18,692,120.PerkinElmer makes up approximately 1.60% of Robecosam Ag’s portfolio.

Other Hedge Funds, Including , Raymond James Financial Services Advisors reduced its stake in PKI by selling 24,532 shares or 63.58% in the most recent quarter. The Hedge Fund company now holds 14,055 shares of PKI which is valued at $764,733. PerkinElmer makes up approx 0.01% of Raymond James Financial Services Advisors’s portfolio.Canada Pension Plan Investment Board reduced its stake in PKI by selling 190 shares or 95.0% in the most recent quarter. The Hedge Fund company now holds 10 shares of PKI which is valued at $544.Blackrock Group Ltd boosted its stake in PKI in the latest quarter, The investment management firm added 6,311 additional shares and now holds a total of 251,632 shares of PerkinElmer which is valued at $13,691,297. PerkinElmer makes up approx 0.01% of Blackrock Group Ltd’s portfolio.Dimensional Fund Advisors Lp reduced its stake in PKI by selling 6,277 shares or 0.96% in the most recent quarter. The Hedge Fund company now holds 647,245 shares of PKI which is valued at $35,333,105. PerkinElmer makes up approx 0.02% of Dimensional Fund Advisors Lp’s portfolio.

PerkinElmer opened for trading at $54.06 and hit $54.63 on the upside on Monday, eventually ending the session at $54.41, with a gain of 0.63% or 0.34 points. The heightened volatility saw the trading volume jump to 2,39,576 shares. Company has a market cap of $5,953 M.

On the company’s financial health, PerkinElmer reported $0.67 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $0.66. The company had revenue of $573.00 million for the quarter, compared to analysts expectations of $575.66 million. The company’s revenue was up 1.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.60 EPS.

Many Wall Street Analysts have commented on PerkinElmer. Mizuho Downgraded PerkinElmer on Aug 5, 2016 to ” Neutral”, Price Target of the shares are set at $56.

PerkinElmer Inc. is a provider of products services and solutions to the diagnostics research environmental industrial and laboratory services markets. The Company operates its business in two segments: Human Health and Environmental Health. The Company’s Human Health segment concentrates on developing diagnostics tools and applications to help detect diseases earlier and more accurately and to accelerate the discovery and development of new therapies. The Company’s Environmental Health segment provides products services and solutions to facilitate the creation of safer food and consumer products more secure surroundings and efficient energy resources. The Company markets its products and services in more than 150 countries.

Leave a Reply

PerkinElmer - Is it time to Sell?

Top Brokerage Firms are advising their investors on PerkinElmer. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.